Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4696-4706
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Figure 1
Figure 1 Flowchart of the study design. Dual therapy: Pegylated-interferon-α and ribavirin; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; NVR: Non-virological response; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin.